VEGFR-2
10 drugs Oncology
5
approved indications
10
Approved Drugs
10
Companies
17
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (10 companies)
✓ All 10 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (17 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
EXELIXIS INC 1 drug
Viatris 1 drug
PF PRISM CV 1 drug
By Therapeutic Area
Other 6 drugs
Oncology 4 drugs
Drugs by Company PRO
EXELIXIS INC 1 drug
Viatris 1 drug
PF PRISM CV 1 drug
Bayer 1 drug
NOVUGEN 1 drug
Novartis 1 drug
EXELIXIS 1 drug
AZURITY 1 drug
Takeda 1 drug
AVEO PHARMS 1 drug
By Therapeutic Area
Other 6 drugs
CABOMETYX, INLYTA, NEXAVAR, VOTRIENT +2 more
Oncology 4 drugs
SORAFENIB TOSYLATE, PAZOPANIB HYDROCHLORIDE, FRUZAQLA, FOTIVDA
Indications Treated
Hepatocellular CarcinomaRenal Cell CarcinomaThyroid CarcinomaSoft Tissue SarcomaMedullary Thyroid CancerFirst-line treatment of advanced renal cell carcinoma in combination with avelumabFirst-line treatment of advanced renal cell carcinoma in combination with pembrolizumabAdvanced renal cell carcinoma after failure of one prior systemic therapyColorectal CancerAdvanced renal cell carcinomaHepatocellular carcinoma previously treated with sorafenibLocally advanced or metastatic differentiated thyroid cancerWell-differentiated pancreatic neuroendocrine tumorsWell-differentiated extra-pancreatic neuroendocrine tumorsUnresectable hepatocellular carcinomaLocally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatmentAdvanced soft tissue sarcoma
All Drugs Targeting VEGFR-2
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| CABOMETYX | EXELIXIS INC | 2016 | 5 | |
| SORAFENIB TOSYLATE | Viatris | 2020 | 3 | Oncology |
| INLYTA | PF PRISM CV | 2012 | 3 | |
| NEXAVAR | Bayer | 2005 | 3 | |
| PAZOPANIB HYDROCHLORIDE | NOVUGEN | 2023 | 2 | Oncology |
| VOTRIENT | Novartis | 2009 | 2 | |
| COMETRIQ | EXELIXIS | 2012 | 1 | |
| RESNIBEN | AZURITY | - | 1 | |
| FRUZAQLA | Takeda | 2023 | 1 | Oncology |
| FOTIVDA | AVEO PHARMS | 2021 | 1 | Oncology |